Industry News
Pharmaceutical Industry News
Discover how Foresight Diagnostics…
Discover how Foresight Diagnostics is pushing MRD detection to new limits with its ultrasensitive technology that has the potential to unlock new actionable insights.
Eli Lilly expanded its AI drug…
Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune candidates. China will lift the import ban on Illumina's DNA sequencers. And more.
Merck & Co.’s charitable…
Merck & Co.’s charitable foundation has committed $22 million to efforts to improve access to care for people with heart disease in the U.S.
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
The approval of Darzalex in…
The approval of Darzalex in smoldering multiple myeloma also offers drugmakers some relief, because the drug’s proposed use had previously drawn criticism from Vinay Prasad, M.D., before he joined the FDA.
This week on “The Top Line,”…
This week on “The Top Line,” we break down what’s known about FDA’s PreCheck, and the parts of the plan that could have the biggest impact on manufacturers.
An amended complaint from several…
An amended complaint from several provider associations argues the vaccine advisory committee's new members were appointed for their anti-vaccine biases, not their experience or credentials, and should be removed under statute and the advisory body's
Akeso has data showing ivonescimab…
Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung cancer, results that can give the red-hot PD-(L)1xVEGF bispecific class a boost.
Eli Lilly and Novo Nordisk have…
Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices.
Nordic Capital and Permira…
Nordic Capital and Permira withdrew their Bavarian Nordic buyout offer after failing to garner enough support from shareholders.
The “most favored nation” drug…
The “most favored nation” drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the British pharma’s $80 billion revenue target by 2030, CEO Pascal Soriot said.
Incyte has expanded its support…
Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa patients, tightening its ties to the community ahead of filings for approval in the indication.
Cencora plans to spend $1 billion…
Cencora plans to spend $1 billion over the next five years to expand its operations in the U.S., including opening a second national distribution center in Ohio.
Some eight months into the launch…
Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that patients’ appetite for the wearable
Teva Pharmaceuticals has a new…
Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia.
The company remains confident in…
The company remains confident in the continued sales potential of Austedo after wrapping up government negotiations that will change the Medicare price for its top-seller in 2027.
Madrigal’s Rezdiffra generated…
Madrigal’s Rezdiffra generated sales of $287 million in the third quarter for a 35% sequential jump from Q2. In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated steatohepatitis
Speaking to reporters during his…
Speaking to reporters during his first quarterly conference call at the company's helm, Maziar Mike Doustdar made clear that expanding access to Novo’s GLP-1 medicines—and continuing to unlock novel sales channels—will be key as the
AstraZeneca is pouring $136…
AstraZeneca is pouring $136 million more into the expansion of an inhalants production base in China, bringing its total investment at the site to $886 million.
With its biosimilars business…
With its biosimilars business thriving, Amgen is in a unique position to comment on U.S. biosimilar policy as the current administration introduces reforms to increase the availability of the copycat drugs. As officials discuss easing